• Vaccine Name: rOka-gD2- HSV-2
• Target Pathogen: Herpes simplex virus type 1 and 2
• Target Disease: Herpes
• Vaccine Ontology ID: VO_0004710
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• gD gene engineering:
  • Type: Recombinant vector construction
  • Description: The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001059
• Preparation: Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
• Immunization Route: Intramuscular injection (i.m.)

Guinea pig Response

• Vaccination Protocol: The guinea pigs were inoculated with three doses of uninfected human fibroblasts, fibroblasts infected with ROka VZV, or fibroblasts infected with ROka-gD2 (Heineman et al., 1995).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The guinea pigs were challenged intravaginally with HSV-2 (Heineman et al., 1995).
• Efficacy: Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001). These experiments demonstrate that the Oka strain of VZV can be used as a live virus vector to protect animals from disease with a heterologous virus (Heineman et al., 1995).